Glaucoma QOL questionnaire ticks the right boxes

Article

The glaucoma-specific health-related quality of life questionnaire, Glau-Qol, demonstrates good correlations with disease progression in patients with glaucoma and ocular hypertension.

The glaucoma-specific health-related quality of life questionnaire, Glau-Qol, demonstrates good correlations with disease progression in patients with glaucoma and ocular hypertension (OHT), according to the results of a study published online ahead of print by Acta Ophthalmologica Scandinavica.

Alain Béchetoille from Paris and colleagues from across France enrolled patients with OHT or glaucoma (n=573) to take part in a cross-sectional psychometric validation study and a separate reproducibility study (n=244). Each subject answered the 36-item Glau-Qol questionnaire, which was designed from in-depth patient interviews.

The clinical validity of the questionnaire was found to be excellent. It clearly demonstrated that as disease severity and visual field impairment increased, health-related quality of life (HRQoL) scores from psychological wellbeing, self-image, daily life, driving, anxiety and burden of treatment domains were negatively affected. Increased age and lower visual acuity were also associated with lower HRQoL scores but to a lesser extent.

Psychometric validation demonstrated acceptable convergent and discriminant validity of the Glau-QoL and good reproducibility, with intra-class correlation coefficients and concordance correlation coefficients ≥0.69.

It was the conclusion of the researchers that the Glau-QoL questionnaire is a valid instrument that demonstrates excellent correlations with disease progression in patients with glaucoma and OHT.

Recent Videos
Dr Rick Lewis discusses the FLigHT procedure and ViaLase laser at the 2024 European Society of Cataract and Refractive Surgeons (ESCRS) meeting
Christiana Dinah speaks about her ASRS presentation, Real-World Treatment Outcomes With Anti-VEGF Therapy in Patients With Retinal Vein Occlusion in the UK
Chase Ludwig, MD, shared an overview of his presentation, which covered real-impact of vitrectomy surgery on the progression of AMD at the annual ASRS meeting in Stockholm, Sweden
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.